Table 6 Prostate cancers found, missed, and biopsies avoided using ClarityDX Prostate model in the validation cohort

From: Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform

Thresholds

GG ≥ 1 PCa found

GG ≥ 1 PCa missed

GG ≥ 2 PCa found

GG ≥ 2 PCa missed

GG ≥ 3 PCa found

GG ≥ 3 PCa missed

GG ≥ 4 PCa found

GG ≥ 4 PCa missed

GG >5 PCa found

GG >5 PCa missed

Biopsies avoideda

Unnecessary biopsies avoidedb

 

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

5

823 (99.9%)

1 (0.1%)

555 (100%)

0 (0.0%)

214 (100%)

0 (0.0%)

81 (100%)

0 (0.0%)

48 (100%)

0 (0.0%)

7 (0.6%)

7 (1.0%)

10

813 (98.7%)

11 (1.3%)

555 (100%)

0 (0.0%)

214 (100%)

0 (0.0%)

81 (100%)

0 (0.0%)

48 (100%)

0 (0.0%)

38 (3.0%)

38 (5.4%)

15

796 (96.6%)

28 (3.4%)

551 (99.3%)

4 (0.7%)

213 (99.5%)

1 (0.5%)

81 (100%)

0 (0.0%)

48 (100%)

0 (0.0%)

98 (7.8%)

94 (13.4%)

20

779 (94.5%)

45 (5.5%)

545 (98.2%)

10 (1.8%)

210 (98.1%)

4 (1.9%)

80 (98.8%)

1 (1.2%)

47 (97.9%)

1 (2.1%)

160 (12.7%)

150 (21.4%)

25

732 (88.8%)

92 (11.2%)

530 (95.5%)

25 (4.5%)

206 (96.3%)

8 (3.7%)

79 (97.5%)

2 (2.5%)

47 (97.9%)

1 (2.1%)

272 (21.6%)

247 (35.2%)

30

689 (83.6%)

135 (16.4%)

517 (93.2%)

38 (6.8%)

203 (94.9%)

11 (5.1%)

79 (97.5%)

2 (2.5%)

47 (97.9%)

1 (2.1%)

361 (28.7%)

323 (46.0%)

35

630 (76.5%)

194 (23.5%)

480 (86.5%)

75 (13.5%)

188 (87.9%)

26 (12.1%)

74 (91.4%)

7 (8.6%)

44 (91.7%)

4 (8.3%)

469 (37.3%)

394 (56.1%)

40

579 (70.3%)

245 (29.7%)

448 (80.7%)

107 (19.3%)

179 (83.6%)

35 (16.4%)

70 (86.4%)

11 (13.6%)

40 (83.3%)

8 (16.7%)

560 (44.6%)

453 (64.5%)

45

519 (63.0%)

305 (37.0%)

409 (73.7%)

146 (26.3%)

165 (77.1%)

49 (22.9%)

62 (76.5%)

19 (23.5%)

37 (77.1%)

11 (22.9%)

655 (52.1%)

509 (72.5%)

50

459 (55.7%)

365 (44.3%)

378 (68.1%)

177 (31.9%)

154 (72.0%)

60 (28.0%)

60 (74.1%)

21 (25.9%)

36 (75.0%)

12 (25.0%)

741 (58.9%)

564 (80.3%)

  1. GG Grade group, PCa Prostate cancer.
  2. aPatients receiving a biopsy but had a ClarityDX Prostate Risk Score below the threshold
  3. bPatients with a negative biopsy or grade group 1 PCa with a ClarityDX Prostate Risk Score below the threshold.
Back to article page